BPA #36E79726A0023

Blanket Purchase Agreement for Specialty Pharmaceuticals by Takeda Pharmaceuticals

This award is a blanket purchase agreement (BPA) awarded to Takeda Pharmaceuticals America, Inc., a prominent pharmaceutical company specializing in innovative medicines. The contract facilitates the supply of several specialty pharmaceuticals, including Cinryze, Kalbitor, Takhzyro, Elaprase, Vpriv, Adzynma, Livtencity, and Gattex. Such medications are critical for treating rare and complex conditions, highlighting the contract's significance to healthcare agencies reliant on these therapies. The scope covers the provision and management of these drugs over a one-year period under the BPA framework, ensuring reliable access and streamlined procurement. This award was issued under an indefinite delivery vehicle, with a prior related federal supply schedule contract supporting pharmaceuticals and hematology-related products, indicating ongoing collaboration and trust between the agency and Takeda. The contract was competitively awarded as part of federal supply schedule arrangements, promoting efficient and compliant acquisition. The performance period extends from late August of 2026 to August 2027, with potential continuation, aligning with long-term pharmaceutical supply needs.

Description

BPA FOR CINRYZE, KALBITOR, TAKHYZRO, ELAPRASE, VPRIV, ADZYNMA, LIVTENCITY, AND GATTEX

View original record